UBS Starts Mineralys Therapeutics, Inc. (MLYS) at Neutral
Tweet Send to a Friend
UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics, Inc. (NASDAQ: MLYS) with a Neutral rating and a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




